[
  {
    "text": "Develop, Manufacture, or Commercialize the Product for use outside the Licensed Field. Furthermore, Xencor hereby covenants and agrees that it shall",
    "bbox": [
      112,
      84,
      1000,
      94
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "not (and shall cause its Affiliates-not to), either directly or through granting a license or other right to, or otherwise facilitating, a Third Party to (a)",
    "bbox": [
      111,
      99,
      1000,
      111
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Develop, Manufacture or Commercialize the Antibody or the Product during the Term, (b) commence any [***] of any [***] that is not the Antibody or a",
    "bbox": [
      111,
      115,
      1000,
      127
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Product and that [***] for use in the Licensed Field, prior to the [***] ([***]th) anniversary of the Effective Date, or (c) Develop, Manufacture or",
    "bbox": [
      110,
      129,
      1000,
      142
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Commercialize any [***] that is not the Antibody or a Product and that [***] for use in the Aimmune Field during the Term. It is the desire and intent of",
    "bbox": [
      110,
      143,
      1000,
      158
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "the Parties that the restrictive covenants contained in this Section 2.4 be enforced to the fullest extent permissible under Applicable Laws and public",
    "bbox": [
      111,
      161,
      1000,
      172
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "policies applied in each jurisdiction in which enforcement is sought. Xencor and Aimmune believe that the restrictive covenants in this Section 2.4 are.",
    "bbox": [
      111,
      176,
      1000,
      188
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "valid and enforceable. However, if any restrictive covenant should for any reason become or be declared by a competent court or competition authority to",
    "bbox": [
      111,
      192,
      1000,
      204
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "be invalid or unenforceable in any jurisdiction, such restrictive covenant shall be deemed to have been amended to the extent necessary in order that.",
    "bbox": [
      110,
      207,
      1000,
      220
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "such provision be valid and enforceable, such amendment shall apply only with respect to the operation of such provision of this Section 2.4 in the",
    "bbox": [
      112,
      224,
      1000,
      234
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "particular jurisdiction in which such declaration is made. Further, both Parties agree that [***] of this Agreement..",
    "bbox": [
      110,
      238,
      934,
      251
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "2.5 Progress Updates. Aimmune shall keep Xencor informed as to its progress and activities relating to the Development, Manufacture and",
    "bbox": [
      156,
      269,
      1000,
      282
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Commercialization of the Product on [***] basis (i.e., every [***] ([***]) months), including by providing updates on the status of studies necessary for",
    "bbox": [
      111,
      285,
      1000,
      298
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "obtaining Regulatory Approval with respect to the Product, regulatory matters and meetings with Regulatory Authorities with respect to the Product, and",
    "bbox": [
      112,
      301,
      1000,
      313
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Commercialization activities commencing no later than [***] ([***]) year prior to the date on which Aimmune estimates the First Commercial Sale of",
    "bbox": [
      111,
      316,
      1000,
      329
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Product will occur. Additionally, to the extent applicable, such updates shall include summaries of Aimmune's Development plans for the Product for the",
    "bbox": [
      111,
      331,
      1000,
      343
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "ensuing [***] ([***]) year time period. Any information disclosed under this Section 2.5 shall be treated as Confidential Information as defined in Section",
    "bbox": [
      111,
      347,
      1000,
      360
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "12.1.",
    "bbox": [
      111,
      363,
      145,
      375
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "2.6 Upstream Agreement. During the Term, neither Xencor nor any of its Affiliates shall (a) encumber any GPEx Technology, as defined in the",
    "bbox": [
      156,
      394,
      1000,
      406
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Upstream Agreement, to the extent included within the Xencor Technology, or commit any act or permit the occurrence of any omission that would cause",
    "bbox": [
      111,
      409,
      1000,
      422
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "the breach or termination of the Upstream Agreement, or otherwise knowingly take actions or permit omissions that would adversely affect the rights.",
    "bbox": [
      111,
      425,
      1000,
      437
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "granted to Aimmune hereunder with respect to the Xencor Patents and Xencor Know-How, or (b) without Aimmune's prior written consent, amend or",
    "bbox": [
      110,
      440,
      1000,
      453
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "otherwise modify or permit to be amended or modified, the Upstream Agreement in any respect that would adversely affect Aimmune's rights with respect",
    "bbox": [
      110,
      456,
      1000,
      468
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "to, the Antibody or Products. Xencor shall promptly notify Aimmune upon Xencor's becoming aware of any alleged, threatened, or actual breach of the",
    "bbox": [
      111,
      472,
      1000,
      484
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Upstream Agreement by either Party and shall not take any action that would reasonably give rise to the right of the counterparty to terminate the",
    "bbox": [
      112,
      487,
      1000,
      499
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Upstream Agreement.",
    "bbox": [
      113,
      504,
      270,
      514
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "2.7 Technology Transfer. Xencor shall use Commercially Reasonable Efforts to transfer, and Aimmune shall use Commercially Reasonable Efforts",
    "bbox": [
      156,
      534,
      1000,
      546
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "to receive, the Xencor Know-How, Regulatory Materials, and Regulatory Data, in each case, as identified on Schedule 2.7 to",
    "bbox": [
      111,
      549,
      1000,
      561
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "15",
    "bbox": [
      662,
      565,
      681,
      576
    ],
    "label": 15,
    "category": "Termination For Convenience"
  },
  {
    "text": "Source: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020",
    "bbox": [
      133,
      1000,
      575,
      1000
    ],
    "label": 15,
    "category": "Termination For Convenience"
  }
]